NovaRock Biotherapeutics

NBL-020 Clin1 multiple cancers; NBL-12 Clin1 psoriasis, HS, IBD; 10 undisclosed programs RD/Clin0 oncology, immuno-oncology, asthma, atopic dermatitis, undisclosed

NovaRock Biotherapeutics is developing antibody therapies for cancer and autoimmune diseases. There are various ways antibodies can be used in therapeutic strategies. NovaRock is using their antibody discovery platforms to enhance the speed, efficiency and quality of antibody production. This includes their antibody generation platform for in-parallel binding and functional screening, the in vivo characterization platform, for multi-dimensional profiling of lead candidates and the translational studies platform, to conduct complex ex vivo and in vivo translational models. NovaRock has established a broad pipeline with programs in oncology, immuno-oncology and immunology now entering clinical investigation.

Jobs: